ConductScience.org, home

Paper38832007

Hallmarks of cancer resistance.

Tufail M and 8 others. iScience, 2024. Cited by 93 papers, by iCite.

Cite this record

ConductScience Library. Hallmarks of cancer resistance. Papers, record 38832007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38832007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hallmarks of cancer resistance.
PubMed
Journal
iScience
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
93
iCite
Relative citation ratio, by iCite
13.73, provisional
iCite
Revised in PubMed
2024-06-07
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tufail MMuhammad
2Hu JJJia-Ju
3Liang JJie
4He CYCai-Yun
5Wan WDWen-Dong
6Huang YQYu-Qi
7Jiang CHCan-Hua
8Wu HHong
9Li NNing

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References262

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133732706Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment.Front Cell Dev Biol2021https://conductscience.org/library/papers/33732706PubMed
230429213Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.Mol Cancer Res2019https://conductscience.org/library/papers/30429213PubMed
329455658Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Mol Cancer2018https://conductscience.org/library/papers/29455658PubMed
437898723Immune check points in cancer treatment: current challenges and perspectives.Br J Cancer2023https://conductscience.org/library/papers/37898723PubMed
536056935IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.Immunogenetics2023https://conductscience.org/library/papers/36056935PubMed
635659296Characteristics of the cancer stem cell niche and therapeutic strategies.Stem Cell Res Ther2022https://conductscience.org/library/papers/35659296PubMed
737483493Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells.Front Oncol2023https://conductscience.org/library/papers/37483493PubMed
828274726A population genetics perspective on the determinants of intra-tumor heterogeneity.Biochim Biophys Acta Rev Cancer2017https://conductscience.org/library/papers/28274726PubMed
935844605Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.Front Immunol2022https://conductscience.org/library/papers/35844605PubMed
1034484295The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review.Front Genet2021https://conductscience.org/library/papers/34484295PubMed
1135933332Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis.BMC Cancer2022https://conductscience.org/library/papers/35933332PubMed
1235850748Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes.BMC Cancer2022https://conductscience.org/library/papers/35850748PubMed
1332799866CircRNAs in anticancer drug resistance: recent advances and future potential.Mol Cancer2020https://conductscience.org/library/papers/32799866PubMed
1436313628The role of BCL-2 family proteins in regulating apoptosis and cancer therapy.Front Oncol2022https://conductscience.org/library/papers/36313628PubMed
1535505363Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells.Stem Cell Res Ther2022https://conductscience.org/library/papers/35505363PubMed
1631792354Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.Nat Rev Clin Oncol2020https://conductscience.org/library/papers/31792354PubMed
1728389777Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.Angiogenesis2017https://conductscience.org/library/papers/28389777PubMed
1833343366Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer.Front Pharmacol2020https://conductscience.org/library/papers/33343366PubMed
1937819576Roles of circRNAs in regulating the tumor microenvironment.Med Oncol2023https://conductscience.org/library/papers/37819576PubMed
2034867402Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.Front Pharmacol2021https://conductscience.org/library/papers/34867402PubMed

See all 262 referencesDownload CSV of references

Cited by69

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.

PMIDTitleJournalYearIn PapersSource
42943246Ascorbate Enhances the Cytotoxicity of the Manganese-Curcumin-Triphenylphosphonium Complex in Human Cancer Cells.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943246PubMed
42936218Flavonoids in cancer pharmacology: molecular mechanisms, tumor microenvironment regulation, and drug resistance.Front Pharmacol2026https://conductscience.org/library/papers/42936218PubMed
42924173A bibliometric evolution of molecular mechanisms and emerging research trends of therapeutic resistance in oral cancer.J Dent Sci2026https://conductscience.org/library/papers/42924173PubMed
42769871Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies.Oncol Res2026https://conductscience.org/library/papers/42769871PubMed
42640371Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Mol Biomed2026https://conductscience.org/library/papers/42640371PubMed
42588713Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers (Basel)2026https://conductscience.org/library/papers/42588713PubMed
42367805MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Front Immunol2026https://conductscience.org/library/papers/42367805PubMed
42358772pH-Responsive Materials for Therapy and Precision Biomedical Imaging.Chem Biomed Imaging2026https://conductscience.org/library/papers/42358772PubMed
42357543Andean Berry (Vaccinium meridionale Swartz) Juice Promotes Cytotoxic and Proapoptotic Effects in Human Early-Stage and Metastatic Colorectal Cancer Cells.Molecules2026https://conductscience.org/library/papers/42357543PubMed
42352984The Regulatory Network of FOXM1: Orchestrating Cancer Progression and Resistance to Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42352984PubMed
42352266The Enigmatic Tumor Suppressor p53 Biomolecule: Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine.Biomolecules2026https://conductscience.org/library/papers/42352266PubMed
42233108Exploration of miR-326 delivery via biocompatible polymeric nanoparticles in medulloblastoma: A preliminary study.Mol Ther Nucleic Acids2026https://conductscience.org/library/papers/42233108PubMed
42196266Machine Learning-Based Identification of Biomarkers for Early-Stage Non-Small Cell Lung Cancer Through Gene Expression Analysis.Int J Mol Sci2026https://conductscience.org/library/papers/42196266PubMed
42193240Regulation of Ferroptosis Sensitivity in Hepatocellular Carcinoma Cells by Lysosomal Ion Channels TPC2 and TRPML1.Antioxidants (Basel)2026https://conductscience.org/library/papers/42193240PubMed
42172791Translational issues with phototherapy of cancer.Transl Oncol2026https://conductscience.org/library/papers/42172791PubMed
42146504USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality.bioRxiv2026https://conductscience.org/library/papers/42146504PubMed
421363093D-QSAR, Molecular Docking, Molecular Dynamics Simulation, and Pharmacokinetic Prediction of 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as PI3Kδ Inhibitors.Curr Med Chem2026https://conductscience.org/library/papers/42136309PubMed
42123502Anticancer Activity of the Antimicrobial Myristoylated Peptide Myr-B in HeLa Cells: Cytotoxic, Membrane-Disruptive and Proteomic Insights.Int J Mol Sci2026https://conductscience.org/library/papers/42123502PubMed
42123327Network-Guided Identification of Plant-Derived Modulators of Stress-Adaptive Signalling in Neuroblastoma.Int J Mol Sci2026https://conductscience.org/library/papers/42123327PubMed
42082974Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42082974PubMed

See all 69 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38832007

GET https://conductscience.org/api/papers/v1/38832007/references?page=2